Announcement on Resolutions of the 2nd Meeting of the 6th Board of Directors
Securities code: 603520 Securities abbreviation: Stellie Announcement number: 2026-032
Zhejiang Stell Pharmaceutical Co., Ltd.
Announcement on the Resolutions of the Second Meeting of the Sixth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Convening of board of directors meetings
(1) The second meeting of the sixth board of directors of Zhejiang Stell Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on August 28, 2026, on-site and via communication, and voting was conducted on-site and via communication.
(2) The company has notified all directors by email and communication on August 18, 2026.
(3) Eight directors should attend this meeting, and eight directors actually attended, including directors Mr. Hu Jinsheng, Mr. Shen Weiyi, Mr. Yang Zhijun, Ms. Mao Meiying, Mr. Zhang Xiaoke, Mr. Hu Jiming, and Mr. Zheng Fangwei participated by communication.
(4) This meeting was convened and chaired by Chairman Hu Jian.
(5) This meeting was held in compliance with the relevant provisions of the "Company Law of the People's Republic of China" and relevant laws, regulations, normative documents and the "Articles of Association".
2. Review status of board of directors meeting
(1) The voting results of the “Proposal on the Full Text and Summary of the Company’s 2026 Semi-annual Report” were reviewed and approved: 8 votes in favor, 0 votes against, and 0 abstentions.
After deliberation, the board of directors unanimously agreed that the full text and summary of the company's 2026 semi-annual report fully reflect the company's operating results, financial status, corporate governance and other relevant conditions in the first half of 2026. The content of the report is true, accurate and complete, and there are no false records, misleading statements or major omissions.
For the full text and summary of the company's 2026 semi-annual report, please refer to the relevant content disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on August 31, 2026.
This proposal does not need to be submitted to the shareholders' meeting for review.
(2) Consideration and approval of the “Proposal on the Company’s 2026 Interim Profit Distribution Plan”
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
For details of the 2026 interim profit distribution plan, please refer to the relevant content disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on August 31, 2026.
This proposal does not need to be submitted to the shareholders' meeting for review.
(3) Consideration and approval of the “Proposal on the Semi-annual Evaluation Report of the Company’s 2026 Special Action Plan for Improving Quality, Increasing Efficiency and Focusing on Returns”
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
For details of the semi-annual evaluation report of the company’s 2026 special action plan to improve quality, efficiency and return, please refer to the relevant content disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on August 31, 2026.
This proposal does not need to be submitted to the shareholders' meeting for review.
(4) Consideration and approval of the “Proposal on Appointment of Secretary to the Company’s Board of Directors”
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
After deliberation, the board of directors unanimously agreed to appoint Mr. Zhang Yi as the secretary of the company's board of directors, with a term starting from the date of review and approval by the board of directors and ending on the expiration date of the sixth session of the board of directors. For details, please refer to the relevant content disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on August 31, 2026.
This proposal does not need to be submitted to the shareholders' meeting for review.
(5) Consideration and approval of the “Proposal on the Appointment of the Company’s Securities Affairs Representative”
Voting results: 8 votes in favor, 0 votes against, and 0 abstentions.
In accordance with the relevant provisions of the "Articles of Association of Zhejiang Stell Pharmaceutical Co., Ltd." and the company's operation and management needs, the board of directors agreed to appoint Mr. He Binyi as the company's securities affairs representative to assist the secretary of the board of directors in performing various duties. Mr. He Binyi has the necessary professional knowledge to serve as a securities affairs representative and has good professional ethics. His qualifications are in compliance with the provisions of the Company Law, the Stock Listing Rules of the Shanghai Stock Exchange and other relevant laws, regulations and normative documents.
This proposal does not need to be submitted to the shareholders' meeting for review.
Announcement is hereby made.
Board of Directors of Zhejiang Stell Pharmaceutical Co., Ltd.
Attachment on August 31, 2026:
Resume of Mr. He Binyi, the company’s securities affairs representative:
He Binyi, male, Chinese nationality, Han nationality, was born in October 1997. He graduated from Zhengzhou University with a bachelor's degree in bioinformatics. From 2019 to 2025, he served as the overseas procurement, strategic account project manager, and board office assistant of Shenzhen Ruiyali Group Co., Ltd. He joined the company in 2025 and has served as the head of the company's International Business Department II.